US Patent 12,564,561 (Drug Product) Scope, Claim-by-Claim Coverage, and Landscape

What does US 12,564,561 claim cover?

US 12,564,561 is directed to a ready-to-use, hermetically sealed, intravenous collapsible drip bag containing a phenylephrine aqueous formulation at pH 3.0 to 3.4 and specific impurity control after storage, with additional structural requirements for the bag material and barrier/oxygen performance. The claims are narrow in composition and storage-impurity performance, and broad in packaging format (collapsible drip bag with specified interior gas/liquid fractions).

The independent claim sets the core enforceable boundaries:

Packaging: hermetically sealed, collapsible IV drip bag with two opposed walls sealed at peripheries, including an inner ply of translucent or transparent polypropylene.
Internal volumes: 75 to 550 mL liquid; 0 to 25% gaseous headspace.
Formulation: phenylephrine (free base or salt) 0.001 to 2.0 mg/mL, a tonicity agent, an acidic pH adjusting agent, and water.
pH constraint: liquid formulation pH 3.0 to 3.4.
Exclusions: excludes antioxidants and chelating agents.
Stability/impurity: “no more than 1% degradants or impurities after three months at 40°C and 75% RH.”
Specific bag permeability option (dependent claim): bag wall oxygen transmission rate (OTR) > 100 cm³·20 μm/m²·day·atm at room temperature and atmospheric pressure.

Dependent claims narrow to specific dose strengths and preservative absence:

Claim 2: phenylephrine hydrochloride at 0.08 mg/mL or 0.4 mg/mL.
Claim 3: absence of an antimicrobial preservative.
Claim 4: oxygen transmission rate above the stated threshold.

What is the claim scope at the formulation level?

Key composition gates (Claim 1(d) and 1(e))

To infringe Claim 1, an asserted product must satisfy, simultaneously:

Active: phenylephrine or pharmaceutically acceptable salt at 0.001 to 2.0 mg/mL.
Vehicle system: includes:
- tonicity agent,
- acidic pH adjusting agent,
- water.
Final pH: 3.0 to 3.4.

Practical coverage implication: The pH window and active concentration window are the first hard filters. If the commercial phenylephrine product operates outside pH 3.0 to 3.4, it likely falls outside Claim 1 even if the bag format is identical.

Exclusions and stability are part of claimability (Claim 1(d) plus “excludes” and “no more than 1%”)

Claim 1 requires both:

Exclusion: the formulation excludes antioxidants and chelating agents.
Performance: ≤1% degradants or impurities after 3 months at 40°C/75% RH.

Practical coverage implication: Even if a product has the right actives and pH, it can avoid the claim if it includes antioxidants/chelating agents, or if its impurity/degradant level after the specified stress storage exceeds the 1% threshold.

Headspace and liquid-fill define the container content relationship (Claim 1(c)(i)-(ii))

Claim 1 requires the interior volume to be split between:

liquid volume: 75 to 550 mL, and
gaseous headspace: 0 to 25% of interior volume.

Practical coverage implication: A product with the same phenylephrine formulation but that uses a different headspace fraction (for example, larger gas fractions) can fall outside the claim.

What is the claim scope at the packaging/material level?

Bag construction (Claim 1(a) and 1(b))

Claim 1 recites a:

hermetically sealed intravenous ready-to-use collapsible drip bag;
two opposed walls sealed around peripheries;
inner ply is translucent or transparent polypropylene.

Practical coverage implication: The claim is not satisfied by generic IV bags unless they are (i) hermetically sealed and (ii) match the specific multilayer structure requirement where the inner ply is translucent or transparent polypropylene.

Oxygen transmission rate (Claim 4)

Claim 4 adds a permeability limitation:

OTR > 100 cm³·20 μm/m²·day·atm (room temperature, atmospheric pressure).

Practical coverage implication: Claim 4 is a narrower subset of Claim 1. Products that match Claim 1 but use higher-barrier oxygen-impermeable structures (lower OTR) avoid Claim 4 while still potentially meeting Claim 1.

What do the dependent claims do to scope?

Claim 2: specific strengths

Claim 2 narrows Claim 1 by requiring phenylephrine hydrochloride at:

0.08 mg/mL or 0.4 mg/mL (based on hydrochloride salt weight).

Claim 3: no antimicrobial preservative

Claim 3 excludes inclusion of an antimicrobial preservative. If a marketed product includes a preservative, it avoids Claim 3, though it still might infringe Claim 1 depending on whether the preservative also counts as an antioxidant/chelating agent (Claim 1 excludes those specific categories) and whether stability/impurity performance fits the 1% limit.

How would infringement analysis usually be framed for a competitor product?

A practical mapping to the claim elements looks like this:

Element	Claim 1 requirement	Primary “design-around” levers
Container format	hermetically sealed collapsible IV drip bag with two opposed walls sealed around peripheries	switch bag format not meeting “hermetically sealed collapsible drip bag”
Inner ply	translucent/transparent polypropylene inner ply	replace inner ply material (non-PP or non-transparent/translucent)
Fill volumes	75 to 550 mL liquid; 0 to 25% headspace	adjust fill/headspace outside ranges
Active and concentration	phenylephrine 0.001 to 2.0 mg/mL	change concentration outside window or use different active form not within “phenylephrine or salt”
pH	pH 3.0 to 3.4	adjust pH outside window
Exclusions	excludes antioxidants and chelating agents	include antioxidant/chelator categories (if permissible)
Stability/impurities	≤1% degradants/impurities after 3 mo at 40°C/75% RH	formulation changes that raise degradant fraction above the threshold (or address storage conditions to avoid the claimed stress test outcome)
Specific packaging permeability	(Claim 4) OTR > 100 cm³·20 μm/m²·day·atm	use lower OTR barrier packaging

What is the likely “patent landscape” shape around this claim set?

Because the claims combine (1) phenylephrine formulation constraints with (2) specific IV bag architecture and headspace, the landscape is best understood as overlapping clusters:

Phenylephrine injectable formulations
- Patents and filings typically cover phenylephrine concentration ranges, pH adjustment, tonicity agents, and stability/impurity control.
- Claim 1 imposes a tight pH band (3.0 to 3.4) and a specific impurity limit after defined stress storage.
Plastic IV container and material barrier patents
- Another cluster is packaging: oxygen transmission rate, hermeticity, collapsible bag design, and multilayer construction (inner ply material).
- Claim 4 specifically ties oxygen permeability to performance.
Nitty-gritty: headspace and fill-volume ratios
- A packaging-formulation interface cluster exists where stability is managed via headspace gas fraction, fill volume, and oxygen availability.
Preservative-free and antioxidant-free strategies
- Claim 1 excludes antioxidants and chelating agents.
- Claim 3 excludes antimicrobial preservatives.
- These exclusions put pressure on companies that otherwise rely on common stabilization recipes.

Net effect: Competitors must align both the chemistry and the container performance to stay within the protected space. Many “formulation-only” workarounds fail because oxygen/headspace and container material features remain claim-critical.

Where are the strongest enforceability anchors?

The most legally potent anchors in this claim set are the elements that function as objective, testable boundaries:

pH 3.0 to 3.4
Active concentration window (0.001 to 2.0 mg/mL)
No antioxidants and no chelating agents
≤1% degradants or impurities after 3 months at 40°C/75% RH
Bag architecture: hermetically sealed collapsible drip bag with translucent/transparent polypropylene inner ply
Headspace 0 to 25%
(Claim 4) OTR > 100 cm³·20 μm/m²·day·atm

These are harder to argue away through equivalency than purely structural, because they tie to compositional performance and measurable packaging oxygen behavior.

What are the key risk points for a generic or “authorized generic” strategy?

1) Matching the packaging and oxygen regime

Even if a formulation meets pH and concentration, failure on:

hermetic sealing,
collapsible drip bag architecture, or
polypropylene inner ply, can avoid Claim 1. But if those features are matched, the oxygen and headspace windows become a risk multiplier, especially where oxygen impacts degradation.

2) Impurity/degradant performance is explicitly claimed

The “≤1% degradants or impurities after three months storage at 40°C/75% RH” is an enforceability lever. A generic developer that focuses on immediate assay and pH may still lose on stress impurity endpoints.

3) Exclusion of antioxidants/chelating agents restricts typical stability toolkits

Many phenylephrine formulations use antioxidants or chelating agents to manage degradation pathways. Claim 1 blocks that approach within the claimed formulation.

4) Preservative-free positioning is also constrained (Claim 3)

If a commercial product includes an antimicrobial preservative, it may avoid Claim 3, but not necessarily Claim 1, because Claim 1 does not explicitly exclude all preservatives. Still, preservatives often correlate with formulation classes that can affect degradants, pH, and the antioxidant/chelating exclusion.

How should investors and R&D teams interpret design-around feasibility?

High-leverage design-around (likely): move pH outside 3.0 to 3.4, shift phenylephrine concentration outside 0.001 to 2.0 mg/mL, introduce antioxidants/chelating agents, or target impurity outcomes above the 1% stress threshold. Each of these attacks Claim 1’s substance limits.
Container-focused design-around: switch inner ply material away from translucent/transparent polypropylene or alter headspace fraction. This avoids Claim 1 even if chemistry stays close.
OTR-based design-around: reduce OTR below Claim 4’s threshold to avoid that dependent claim, while still potentially meeting Claim 1 if other elements are met.

Claim chart snapshot (what must be proven for each asserted element)

Claim element	What must be tested/verified in an accused product
Hermetically sealed collapsible IV drip bag	package type, sealing method, hermeticity characterization
Two opposed walls sealed at peripheries	physical construction and lamination/sealing evidence
Inner ply translucent/transparent polypropylene	material identification of inner ply
Liquid volume range	net filled volume measurement (75–550 mL)
Headspace fraction	compute gas headspace as % of interior volume
Phenylephrine concentration range	assay concentration (mg/mL)
pH 3.0–3.4	pH measurement in formulation
Tonicity agent and acidic pH adjusting agent present	formulation composition
Excludes antioxidants and chelating agents	ingredient inventory and analytical confirmation
Impurity/degradants ≤1% after stress	stability-indicating assay at 3 months, 40°C/75% RH
(Claim 2) PhE HCl at 0.08 or 0.4 mg/mL	strength-specific concentration
(Claim 3) no antimicrobial preservative	preservative presence/absence
(Claim 4) OTR > 100 threshold	barrier property measurement per stated test conditions

What is the practical meaning of the absence of antioxidants/chelators?

Claim 1 builds a stability envelope that is achieved without antioxidants and without chelating agents. This tends to narrow the set of commercially plausible formulations:

Formulation recipes that use chelators to bind trace metals and suppress catalytic degradation are excluded.
Formulations that use antioxidants to slow oxidation pathways are excluded.
The claimed impurity limit then becomes the proof point for whichever degradation mitigation remains (pH, ionic strength/tonicity, and container oxygen/headspace management).

Key Takeaways

US 12,564,561 protects a tightly defined phenylephrine IV product: phenylephrine 0.001–2.0 mg/mL, aqueous pH 3.0–3.4, tonicity and acidic pH adjustment, no antioxidants and no chelating agents, and ≤1% degradants/impurities after 3 months at 40°C/75% RH.
Packaging is claim-critical: a hermetically sealed collapsible drip bag with two opposed walls, and an inner ply that is translucent or transparent polypropylene, with 75–550 mL liquid and 0–25% headspace.
Dependent claims narrow further: Claim 2 locks to phenylephrine HCl at 0.08 mg/mL or 0.4 mg/mL; Claim 3 requires no antimicrobial preservative; Claim 4 requires OTR > 100 cm³·20 μm/m²·day·atm.
Design-around is constrained by combined chemistry and container performance: moving pH, concentration, antioxidant/chelating inclusion, or stability endpoints can avoid Claim 1; switching polypropylene inner ply or headspace fraction can also avoid the claim even with similar chemistry.

FAQs

Does matching the phenylephrine pH alone infringe US 12,564,561?
No. Claim 1 also requires the specified bag construction (hermetically sealed collapsible drip bag, two opposed walls, inner translucent/transparently PP ply), the fill/headspace ranges, and the impurity/degradant performance plus antioxidant/chelating exclusions.
Can a product avoid Claim 4 while still potentially infringing Claim 1?
Yes. Claim 4 adds an OTR threshold. A product can match Claim 1’s formulation and packaging features but use a lower OTR bag to avoid the dependent claim.
How does the “≤1% degradants or impurities” requirement affect product positioning?
It is a quantitative stress-storage endpoint at 40°C/75% RH for 3 months. Product development must control stability and impurity formation under that condition, not only initial quality.
If a formulation includes an antimicrobial preservative, does it avoid the patent?
Claim 3 specifically requires absence of an antimicrobial preservative, but Claim 1 does not broadly exclude preservatives. An accused product can still potentially infringe Claim 1 if it meets Claim 1’s other exclusions (antioxidants and chelating agents) and stability/performance limits.
Is the claimed packaging tied to a specific nominal bag size beyond volume?
The claim specifies liquid volume 75–550 mL and headspace 0–25%. It does not set a single nominal size; infringement turns on those quantitative internal content parameters plus the structural and material requirements.

References

[1] United States Patent No. 12,564,561 (claims as provided).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dr Reddys Labs Sa	PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	216830-001	May 30, 2025		RX	Yes	Yes	12,564,561	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	124867	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2022172253	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,564,561

Which drugs does patent 12,564,561 protect, and when does it expire?

Summary for Patent: 12,564,561